A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

被引：0
|
作者：
Nikol Snoeren
Emile E Voest
Andre M Bergman
Otilia Dalesio
Henk M Verheul
Rob AEM Tollenaar
Joost RM van der Sijp
Sander B Schouten
Inne HM Borel Rinkes
R van Hillegersberg
机构：
[1] University Medical Center Utrecht,Department of Surgical Oncology
[2] University Medical Center Utrecht,Department of Medical Oncology
[3] Antonie van Leeuwenhoek Hospital,Department of Medical Oncology
[4] Antonie van Leeuwenhoek Hospital,Department of Biometrics
[5] VU Medical Center De Boelelaan 1117,Department of Medical Oncology
[6] Department of Surgery,undefined
[7] Leiden,undefined
[8] Department of Surgery,undefined
来源：
BMC Cancer | / 10卷
关键词：
Vascular Endothelial Growth Factor; Bevacizumab; Liver Metastasis; Disease Free Survival; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer: Final safety findings from a randomized phase III trial
    Schmoll, H.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    de Braud, F.
    Haller, D.
    ANNALS OF ONCOLOGY, 2006, 17 : 25 - 26
  • [42] Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
    Yamazaki, K.
    Nagase, M.
    Tamagawa, H.
    Ueda, S.
    Tamura, T.
    Murata, K.
    Nakajima, T. Eguchi
    Baba, E.
    Tsuda, M.
    Moriwaki, T.
    Esaki, T.
    Tsuji, Y.
    Muro, K.
    Taira, K.
    Denda, T.
    Funai, S.
    Shinozaki, K.
    Yamashita, H.
    Sugimoto, N.
    Okuno, T.
    Nishina, T.
    Umeki, M.
    Kurimoto, T.
    Takayama, T.
    Tsuji, A.
    Yoshida, M.
    Hosokawa, A.
    Shibata, Y.
    Suyama, K.
    Okabe, M.
    Suzuki, K.
    Seki, N.
    Kawakami, K.
    Sato, M.
    Fujikawa, K.
    Hirashima, T.
    Shimura, T.
    Taku, K.
    Otsuji, T.
    Tamura, F.
    Shinozaki, E.
    Nakashima, K.
    Hara, H.
    Tsushima, T.
    Ando, M.
    Morita, S.
    Boku, N.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1539 - 1546
  • [43] AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.
    De Gramont, A.
    Van Cutsem, E.
    Tabernero, J.
    Moore, M. J.
    Cunningham, D.
    Rivera, F.
    Im, S.
    Makrutzki, M.
    Shang, A.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [44] Capecitabine plus oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results
    Rothenberg, M.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J.
    Goel, R.
    Gollins, S.
    Siu, L.
    Cunningham, D.
    EJC SUPPLEMENTS, 2007, 5 (04): : 238 - 239
  • [45] Phase II study of resection of primary colorectal cancer and synchronous liver metastasis after S-1+oxaliplatin (SOX) plus bevacizumab (Bmab) therapy and adjuvant S-1 chemotherapy
    Miura, T.
    Morohashi, H.
    Sakamoto, Y.
    Yoshida, T.
    Sato, K.
    Ishido, K.
    Kudo, D.
    Kimura, N.
    Hakamada, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] ADJUVANT REGORAFENIB IN STAGE IV COLORECTAL CANCER (CRC) AFTER CURATIVE TREATMENT OF LIVER METASTASES: A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY (COAST)
    Eric, Van Cutsem
    Takayuki, Yoshino
    Xu Rui-Hua
    John, Zalcberg
    Daniel, Sargent
    Michael, Choti
    Mark, Rutstein
    Lisa, Cupit
    Iris, Kuss
    Axel, Grothey
    ANNALS OF ONCOLOGY, 2014, 25 : 92 - 92
  • [47] Bevacizumab plus capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients with metastatic colorectal cancer (mCRC) suitable for combination chemotherapy: Efficacy and safety findings from the phase II BECOX study (GEMCAD Study Group)
    Feliu, J.
    Salud, A.
    Safont, M. J.
    Garcia-Giron, C.
    Aparicio, J.
    Vera, R.
    Serra, O.
    Casado, E.
    Jorge, M.
    Maurel, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S553 - S553
  • [48] Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer.
    Saunders, Mark P.
    Lang, Istvan
    Marcuello, Eugenio
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dongbok
    Jonker, Derek J.
    Osborne, Stuart
    Loeffler, Markus
    Waterkamp, Daniel
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Final safety findings from a randomized phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.
    Schmoll, H. J.
    Tabernero, J.
    Nowacki, M.
    Maroun, J.
    Price, T.
    Lim, R.
    Van Cutsem, E.
    De Braud, F.
    Haller, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 163S - 163S
  • [50] Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG).
    Pectasides, D. G.
    Xanthakis, I.
    Makatsoris, T.
    Samantas, E.
    Varthalitis, I.
    Papaxoinis, G.
    Papakotoulas, P.
    Boumakis, E.
    Papandreou, C.
    Fountzilas, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345